These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29329784)

  • 21. Improving the assessment of heart toxicity for all new drugs through translational regulatory science.
    Johannesen L; Vicente J; Gray RA; Galeotti L; Loring Z; Garnett CE; Florian J; Ugander M; Stockbridge N; Strauss DG
    Clin Pharmacol Ther; 2014 May; 95(5):501-8. PubMed ID: 24336137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of bioinformatics in diabetes drug development--and precision medicine.
    Dangi-Garimella S
    Am J Manag Care; 2014 May; 20(8 Spec No.):E1. PubMed ID: 25617937
    [No Abstract]   [Full Text] [Related]  

  • 23. Rare diseases in children: towards better and fairer treatment.
    Lancet; 2014 Jul; 384(9939):208. PubMed ID: 25042219
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug development needs a new brand of science.
    Fitzgerald G
    Nature; 2010 Dec; 468(7326):869. PubMed ID: 21164436
    [No Abstract]   [Full Text] [Related]  

  • 25. The 6th drug discovery for neurodegeneration conference: an intensive course on translating research into drugs.
    Chico LK; Watterson DM
    Expert Opin Drug Discov; 2012 Dec; 7(12):1225-8. PubMed ID: 23092534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPME as a promising tool in translational medicine and drug discovery: From bench to bedside.
    Goryński K; Goryńska P; Górska A; Harężlak T; Jaroch A; Jaroch K; Lendor S; Skobowiat C; Bojko B
    J Pharm Biomed Anal; 2016 Oct; 130():55-67. PubMed ID: 27233133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partnering for therapeutics discovery.
    Colvis CM; Devaney S; Brady LS; Hudson KL
    Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
    [No Abstract]   [Full Text] [Related]  

  • 28. The Clinical-Translational Physician-Scientist: Translating Bedside to Bench.
    Hunt PW
    J Infect Dis; 2018 Aug; 218(suppl_1):S12-S15. PubMed ID: 30124982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMS.
    Stevenson L; Garofolo F; DeSilva B; Dumont I; Martinez S; Rocci M; Amaravadi L; Brudny-Kloeppel M; Musuku A; Booth B; Dicaire C; Wright L; Mayrand-Provencher L; Losauro M; Gouty D; Arnold M; Bansal S; Dudal S; Dufield D; Duggan J; Evans C; Fluhler E; Fraser S; Gorovits B; Haidar S; Hayes R; Ho S; Houghton R; Islam R; Jenkins R; Katori N; Kaur S; Kelley M; Knutsson M; Lee J; Liu H; Lowes S; Ma M; Mikulskis A; Myler H; Nicholson B; Olah T; Ormsby E; Patel S; Pucci V; Ray C; Schultz G; Shih J; Shoup R; Simon C; Song A; Neto JT; Theobald V; Thway T; Wakelin-Smith J; Wang J; Wang L; Welink J; Whale E; Woolf E; Xu R
    Bioanalysis; 2013 Dec; 5(23):2903-18. PubMed ID: 24107004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Translational medicine].
    Antal J; Timár A
    Orv Hetil; 2011 Nov; 152(47):1894-902. PubMed ID: 22042316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the efficacy of translational medicine by optimally integrating health care, academia and industry.
    Bornstein SR; Licinio J
    Nat Med; 2011 Dec; 17(12):1567-9. PubMed ID: 22146467
    [No Abstract]   [Full Text] [Related]  

  • 32. The reproducibility issue and preclinical academic drug discovery: educational and institutional initiatives fostering translation success.
    Janero DR
    Expert Opin Drug Discov; 2016 Sep; 11(9):835-42. PubMed ID: 27401809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development.
    Kearns GL
    Biomark Med; 2010 Dec; 4(6):783-6. PubMed ID: 21133695
    [No Abstract]   [Full Text] [Related]  

  • 34. European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development.
    Timmerman P; Herling C; Stoellner D; Jaitner B; Pihl S; Elsby K; Henderson N; Barroso B; Fischmann S; Companjen A; Versteilen A; Bates S; Kingsley C; Kunz U;
    Bioanalysis; 2012 Aug; 4(15):1883-94. PubMed ID: 22943619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid.
    Dickinson PA; Kesisoglou F; Flanagan T; Martinez MN; Mistry HB; Crison JR; Polli JE; Cruañes MT; Serajuddin ATM; Müllertz A; Cook JA; Selen A
    J Pharm Sci; 2016 Nov; 105(11):3243-3255. PubMed ID: 27659159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral studies on anxiety and depression in a drug discovery environment: keys to a successful future.
    Bouwknecht JA
    Eur J Pharmacol; 2015 Apr; 753():158-76. PubMed ID: 25460021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translatability: what does it mean in drug discovery?
    Tudor M; Hermes J; Li J
    Drug Discov Today; 2016 Jun; 21(6):865-7. PubMed ID: 27021791
    [No Abstract]   [Full Text] [Related]  

  • 38. Research at the interface of industry, academia and regulatory science.
    Mattes WB; Walker EG; Abadie E; Sistare FD; Vonderscher J; Woodcock J; Woosley RL
    Nat Biotechnol; 2010 May; 28(5):432-3. PubMed ID: 20458309
    [No Abstract]   [Full Text] [Related]  

  • 39. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
    Bashaw ED
    Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A tiered approach to address regulatory drug metabolite-related issues in drug development.
    Ma S; Chowdhury SK
    Bioanalysis; 2014 Mar; 6(5):587-90. PubMed ID: 24620798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.